Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 2/20 | 0.56 |
| ▸ | CDK4 | P11802 | 2/20 | 0.56 |
| ▸ | JAK2 | O60674 | 15/20 | 0.53 |
| ▸ | BRD4 | O60885 | 8/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.51 |
| ▸ | JAK3 | P52333 | 5/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.51 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.49 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.46 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.46 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1655049 | 0.92 | AURKA (0.64) | AURKACDK4JAK2BRD4HDAC6 | |
| SCHEMBL1655013 | 0.91 | JAK2 (0.61) | AURKACDK4JAK2BRD4HDAC6 | |
| SCHEMBL1655187 | 0.91 | AURKA (0.54) | AURKACDK4JAK2BRD4HDAC6 | |
| SCHEMBL3399191 | 0.90 | JAK2 (0.62) | AURKACDK4JAK2BRD4HDAC6 | |
| SCHEMBL3399195 | 0.89 | AURKA (0.55) | AURKACDK4JAK2BRD4HDAC6 | |
| SCHEMBL1657573 | 0.89 | AURKA (0.55) | AURKACDK4JAK2BRD4HDAC6 | |
| SCHEMBL1655002 | 0.89 | JAK2 (0.54) | AURKACDK4JAK2BRD4HDAC6 | |
| SCHEMBL3403256 | 0.89 | AURKA (0.52) | AURKACDK4JAK2BRD4HDAC6 | |
| SCHEMBL27916041 | 0.86 | JAK2 (0.50) | AURKACDK4JAK2BRD4HDAC6 | |
| SCHEMBL1653405 | 0.86 | AURKA (0.53) | AURKACDK4JAK2BRD4HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | claimed |
| US-8420657-B2 | Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
| WO-2009098236-A1 | PYRROLO [2, 3-D] PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | AURKA 755/4885CDK4 186/4885JAK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.